Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Roberta Martiniani"'
Autor:
Roberta Martiniani, Valentina Di Loreto, Chiara Di Sano, Alessandra Lombardo, Anna Marina Liberati
Publikováno v:
Advances in Hematology, Vol 2012 (2012)
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be act
Externí odkaz:
https://doaj.org/article/09c1d03a18744bfc8db84f2e66b9d599
Autor:
Valerio Annessi, Maurizio Zizzo, Magda Zanelli, Paola Parente, Francesca Sanguedolce, Roberta Martiniani, Lorenzo Manzini, Giovanni Martino, Loredana De Marco, Stefano Ascani
Publikováno v:
Medicine. 99:e22335
Introduction Plasmablastic lymphoma (PBL) is an uncommon and aggressive large B-cell lymphoma commonly diagnosed in human immunodeficiency viruses -positive patients. Oral cavity is the most commonly PBL affected site. Most oral PBLs presented as asy
Autor:
Annamaria Rauco, Roberta Martiniani, Stefano Ascani, Fabrizio Liberati, Cristina Zannori, Angelo Genua, Anna Marina Liberati
Background. BV, an anti-CD30 antibody-drug conjugate, has been approved for the treatment of Hodgkin lymphoma (HL) and ALCL. Of interest, BV has shown activity in PTCLs other than ALCL that express low or even undetectable levels of CD30. In particul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::888ab738dcdd54e0829eb32c074c4747
http://hdl.handle.net/11391/1406587
http://hdl.handle.net/11391/1406587
Autor:
Valentina Di Loreto, Roberta Martiniani, Chiara Di Sano, Alessandra Lombardo, Anna Marina Liberati
Publikováno v:
Advances in Hematology, Vol 2012 (2012)
Advances in Hematology
Advances in Hematology
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdaa4dfe5a433c6f0054fba7bf3bfb45
http://hdl.handle.net/11391/986981
http://hdl.handle.net/11391/986981
Autor:
Roberta Pace, Debora Luzi, Anna Marina Liberati, Roberta Martiniani, Lorenzo Falchi, Marta Gubbiotti, Paola Cerroni, Pasqualinda Ferrara, Giulia Braccalenti
Publikováno v:
Blood. 110:4832-4832
Background. There are evidences supporting the existence of a synergism between the proteasome inhibitor bortezomib and anthracyclines. In addition, several in vivo data show synergic-additive effect of bortezomib and pegylated liposomal doxorubicine